Prevalence at the end of AGES II (n = 5170) | ||||||||
---|---|---|---|---|---|---|---|---|
Males | Females | |||||||
Age groups | n | TKR (%) | THR (%) | TJR (%) | n | TKR (%) | THR (%) | TJR (%) |
−69 | 188 | 6.9 | 4.3 | 10.6 | 339 | 5.6 | 8.8 | 13 |
70–74 | 677 | 5.6 | 6.9 | 11.2 | 878 | 7.5 | 8.9 | 15.3 |
75–79 | 673 | 4.5 | 6.7 | 10.5 | 832 | 7.6 | 8.1 | 14.3 |
80–84 | 482 | 6.0 | 7.3 | 13.1 | 685 | 6.0 | 11.5 | 16.6 |
85+ | 175 | 4.3 | 8.6 | 11.4 | 241 | 4.6 | 12.9 | 17.0 |
Total (95%CI) | 2195 | 5.2 (4.3–6.2) | 6.8 (5.8–7.9) | 11.4 (10.1–12.7) | 2975 | 6.7 (5.8–7.6) | 9.6 (8.5–10.6) | 15.2 (13.9–16.5) |
Incidence during five-year follow-up (n = 3133)a | ||||||||
Males | Females | |||||||
Age groups | n | TKR (%) | THR (%) | TJR (%) | n | TKR (%) | THR (%) | TJR (%) |
−69 | 154 | 3.9 | 1.9 | 5.8 | 266 | 3.4 | 5.6 | 8.6 |
70–74 | 500 | 2.8 | 3.6 | 6.2 | 679 | 5.9 | 4.3 | 9.9 |
75–79 | 423 | 2.8 | 3.1 | 5.9 | 507 | 3.2 | 4.1 | 7.1 |
80–84 | 200 | 3.0 | 2.5 | 5.5 | 310 | 1.0 | 4.5 | 5.2 |
85+ | 35 | 0 | 2.9 | 2.9 | 59 | 1.7 | 1.7 | 3.4 |
Total (95%CI) | 1312 | 2.9 (2.0–3.8) | 3.0 (2.1–4.0) | 5.9 (4.6–7.1) | 1821 | 3.8 (2.9–4.7) | 4.4 (3.5–5.3) | 7.9 (6.7–9.1) |